|
業務類別
|
Biotechnology |
|
業務概覽
|
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema. |
| 公司地址
| 250 North Westlake Boulevard, Suite 210, Westlake Village, CA, USA, 91362 |
| 電話號碼
| +1 818 564-4011 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.turntherapeutics.com |
| 員工數量
| 2 |
| Mr. Bradley Evan Burnam |
Chief Executive Officer and Chairman of the Board |
美元 465.74K |
31/03/2026 |
| Mr. Zuraiz Chaudhary |
Interim Chief Financial Officer, Vice President, Finance and Chief Accounting Officer |
美元 152.21K |
31/03/2026 |
| Dr. Neilesh Shailesh Ghodadra |
Chief Medical Officer and Director |
-- |
31/03/2026 |
|
|
| Mr. Arthur F. Golden |
Independent Director |
31/03/2026 |
| Mr. Martin William Dewhurst |
Independent Director |
07/01/2026 |
| Mr. Andrew Gengos, M.B.A. |
Independent Director |
31/03/2026 |
| Mr. Bradley Evan Burnam |
Chief Executive Officer and Chairman of the Board |
31/03/2026 |
| Dr. Neilesh Shailesh Ghodadra |
Chief Medical Officer and Director |
31/03/2026 |
| Dr. Kent Edward Kester |
Independent Director |
31/03/2026 |
|
|
|
|
